While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.

The UK biotech is the first company to file a T-cell receptor therapy with regulators, a class with potential to hit targets unreachable for antibodies and CAR-Ts.

Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.

The promise of Immatics’ T-cell redirecting cancer immunotherapy technology for solid tumors has been spotlighted in early clinical studies in heavily pre-treated and refractory cancer patients.